Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Stoke_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
STK-001
|
| gptkbp:intendedUse |
gptkb:Dravet_syndrome
|
| gptkbp:mechanismOfAction |
antisense oligonucleotide
|
| gptkbp:orphanDrugDesignation |
gptkb:FDA
gptkb:EMA |
| gptkbp:routeOfAdministration |
intrathecal
|
| gptkbp:status |
investigational
|
| gptkbp:targetGene |
gptkb:SCN1A
|
| gptkbp:therapeuticArea |
neurology
|
| gptkbp:bfsParent |
gptkb:Stoke_Therapeutics
|
| gptkbp:bfsLayer |
7
|